அலுவலகம் ஆஃப் ஆர்ஃபந் ப்ராடக்ட்ஸ் வளர்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease VICO Therapeutics, a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for VO659, VICO s investigational antisense oligonucleotide (AON) therapy, for the treatment of Huntington s disease (HD). This news comes only one month after VICO announced that VO659 had received orphan-drug designation for the treatment of spinocerebellar ataxia (SCA). This new designation completes the quartet of orphan designations for VO659 in HD and SCA in both the US and EU.

Noord hollandKostenloser wertpapierhandelRupert sandbrinkGertjan bartlemaDrug administrationLifespring life sciences communicationOffice of orphan products developmentLeiden bio science parkOrphan products developmentChief medical officerOrphan drug designationHuntington diseaseChief executive officerSpring life sciences communicationநூற்த் ஹாலண்ட்ஆயுட்காலம் வாழ்க்கை அறிவியல் தொடர்பு